286 related articles for article (PubMed ID: 17425222)
1. The direct and indirect costs of untreated insomnia in adults in the United States.
Ozminkowski RJ; Wang S; Walsh JK
Sleep; 2007 Mar; 30(3):263-73. PubMed ID: 17425222
[TBL] [Abstract][Full Text] [Related]
2. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
3. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
4. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study.
Kleinman NL; Brook RA; Doan JF; Melkonian AK; Baran RW
J Clin Psychiatry; 2009 Aug; 70(8):1098-104. PubMed ID: 19758521
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers.
Daley M; Morin CM; LeBlanc M; Grégoire JP; Savard J
Sleep; 2009 Jan; 32(1):55-64. PubMed ID: 19189779
[TBL] [Abstract][Full Text] [Related]
6. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.
Snedecor SJ; Botteman MF; Bojke C; Schaefer K; Barry N; Pickard AS
Sleep; 2009 Jun; 32(6):817-24. PubMed ID: 19544759
[TBL] [Abstract][Full Text] [Related]
8. Costs of asthma among US working adults.
Shenolikar R; Song X; Anderson JA; Chu BC; Cantrell CR
Am J Manag Care; 2011 Jun; 17(6):409-16. PubMed ID: 21756011
[TBL] [Abstract][Full Text] [Related]
9. Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.
Gilligan AM; Foster SA; Sainski-Nguyen A; Sedgley R; Smith D; Morrow P
J Occup Environ Med; 2018 Dec; 60(12):1120-1127. PubMed ID: 30199470
[TBL] [Abstract][Full Text] [Related]
10. The direct and indirect cost burden of Crohn's disease and ulcerative colitis.
Gibson TB; Ng E; Ozminkowski RJ; Wang S; Burton WN; Goetzel RZ; Maclean R
J Occup Environ Med; 2008 Nov; 50(11):1261-72. PubMed ID: 19001952
[TBL] [Abstract][Full Text] [Related]
11. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
Jhaveri M; Seal B; Pollack M; Wertz D
Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
[TBL] [Abstract][Full Text] [Related]
12. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.
Botteman MF; Ozminkowski RJ; Wang S; Pashos CL; Schaefer K; Foley DJ
CNS Drugs; 2007; 21(4):319-34. PubMed ID: 17381185
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
15. Insomnia and absenteeism at work. Who pays the cost?
Godet-Cayré V; Pelletier-Fleury N; Le Vaillant M; Dinet J; Massuel MA; Léger D
Sleep; 2006 Feb; 29(2):179-84. PubMed ID: 16494085
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
17. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States.
Pollack M; Seal B; Joish VN; Cziraky MJ
Curr Med Res Opin; 2009 Aug; 25(8):1901-11. PubMed ID: 19530979
[TBL] [Abstract][Full Text] [Related]
18. Health economics of insomnia therapy: implications for policy.
Botteman M
Sleep Med; 2009 Sep; 10 Suppl 1():S22-5. PubMed ID: 19647482
[TBL] [Abstract][Full Text] [Related]
19. Insomnia risks and costs: health, safety, and quality of life.
Rosekind MR; Gregory KB
Am J Manag Care; 2010 Aug; 16(8):617-26. PubMed ID: 20712395
[TBL] [Abstract][Full Text] [Related]
20. The direct economic costs of insomnia in the United States for 1995.
Walsh JK; Engelhardt CL
Sleep; 1999 May; 22 Suppl 2():S386-93. PubMed ID: 10394612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
